Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction.

This research study examines the effectiveness of the drug salmeterol xinafoate in treating horses with a chronic respiratory condition called recurrent airway obstruction. The study found that the drug, given through an aerosol, provided relief lasting about six hours for the horses’ respiratory symptoms.

Research Objectives and Methods

• The primary goal of this study was to examine the onset, the extent and the period of reduced difficulty in breathing (bronchodilation) following the application of aerosolized salmeterol xinafoate in horses suffering from recurrent airway obstruction.
• The study was conducted under randomized control conditions with six horses participating, all of whom had recurrent airway obstruction.
• The researchers used a crossover design, in which the horses received aerosolized treatments of salmeterol xinafoate or no treatment at all.
• The drug was administered through a mask specially made for aerosol delivery in horses.
• After the administration of the drug, the researchers measured several indicators of respiratory function – the subjective rating of airway obstruction (RAO), the maximum change in pleural pressure (deltaPplmax), and pulmonary resistance (RL) – at different times (from 5 minutes to 12 hours).

Results and Conclusions

• The results revealed that the administration of salmeterol xinafoate improved the deltaPpl and RL from 15 minutes to 6 hours post-administration.
• The RAO improved between 15 minutes and 2 hours following the administration of the drug.
• The maximum effect of the drug was observed 30 to 60 minutes post-administration, marked by a decrease in deltaPpl by 59 +/- 19% and a decrease in RL by 56 +/- 13%.
• However, the values for deltaPpl and RL were not different from their baseline values 8 hours post-administration, indicating the drug’s effects were not long-lasting.
• One key conclusion was that salmeterol xinafoate had a duration of action of about 6 hours in these horses.
• The drug’s peak bronchodilation outcomes were slightly deferred (30 to 60 minutes) and were comparable in magnitude to those of short-acting beta2-adrenergic agonists.
• The results suggest that salmeterol xinafoate can offer moderated sustained bronchodilation in horses experiencing recurrent airway obstruction and could be an effective medication for long-term control of this condition.